Competitive inhibition of IDO with 1-methyl-d-tryptophan (1-MT) has been widely used in preclinical studies, and has been shown to suppress progression of IDO-expressing ovarian cancer cells in a syngeneic mouse model [90]. This evidence concerns the gene IDO1 and ovarian carcinoma.